BIOMAT Database Logo BIOMAT Database Logo

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. 2000

M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven, Belgium.

The occurrence of factor VIII (fVIII) inhibitory antibodies is a rare complication of fVIII substitution therapy in mild/moderate hemophilia A patients. fVIII mutations in certain regions such as the C1 domain are, however, more frequently associated with inhibitor, for reasons which remain unclear. To determine whether inhibitors could map to the mutation site, we analyzed at the clonal level the immune response of such a patient with an inhibitor to wild-type but not self-fVIII and an Arg2150His substitution in the C1 domain. Immortalization of the patient B lymphocytes provided a cell line producing an anti-fVIII IgG4kappa antibody, LE2E9, that inhibited fVIII cofactor activity, following type 2 kinetics and prevented fVIII binding to von Willebrand factor. Epitope mapping with recombinant fVIII fragments indicated that LE2E9 recognized the fVIII C1 domain, but not the Arg2150His-substituted C1 domain. Accordingly, LE2E9 did not inhibit Arg2150His fVIII activity. These observations identify C1 as a novel target for fVIII inhibitors and demonstrate that Arg2150His substitution alters a B-cell epitope in the C1 domain, which may contribute to the higher inhibitor incidence in patients carrying such substitution. (Blood. 2000; 95:156-163)

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007135 Immunoglobulin Variable Region That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions. Variable Region, Ig,Variable Region, Immunoglobulin,Framework Region, Immunoglobulin,Fv Antibody Fragments,Fv Fragments,Ig Framework Region,Ig Variable Region,Immunoglobulin Framework Region,Immunoglobulin Fv Fragments,Immunoglobulin V,Antibody Fragment, Fv,Antibody Fragments, Fv,Fragment, Fv,Fragment, Fv Antibody,Fragment, Immunoglobulin Fv,Fragments, Fv,Fragments, Fv Antibody,Fragments, Immunoglobulin Fv,Framework Region, Ig,Framework Regions, Ig,Framework Regions, Immunoglobulin,Fv Antibody Fragment,Fv Fragment,Fv Fragment, Immunoglobulin,Fv Fragments, Immunoglobulin,Ig Framework Regions,Ig Variable Regions,Immunoglobulin Framework Regions,Immunoglobulin Fv Fragment,Immunoglobulin Variable Regions,Regions, Immunoglobulin Variable,Variable Regions, Ig,Variable Regions, Immunoglobulin
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005803 Genes, Immunoglobulin Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity). Genes, Ig,Immunoglobulin Genes,Gene, Ig,Gene, Immunoglobulin,Ig Gene,Ig Genes,Immunoglobulin Gene
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
Unique surface-exposed hydrophobic residues in the C1 domain of factor VIII contribute to cofactor function and von Willebrand factor binding.
February 2020, Journal of thrombosis and haemostasis : JTH,
M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.
May 1991, Blood,
M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding.
May 2003, Thrombosis and haemostasis,
M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
October 2008, Journal of thrombosis and thrombolysis,
M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
Antibody to human factor VIII/von Willebrand factor inhibits collagen-induced platelet aggregation and release.
January 1980, Thrombosis research,
M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
Amino group modification inhibits ristocetin cofactor activity of human von Willebrand factor.
September 1982, Biochemical and biophysical research communications,
M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
March 1993, Thrombosis and haemostasis,
M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
A role for the C2 domain of factor VIII in binding to von Willebrand factor.
April 1994, The Journal of biological chemistry,
M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
Enhancement of factor VIII-von Willebrand factor ristocetin cofactor activity by monoclonal antibodies.
August 1985, Thrombosis and haemostasis,
M Jacquemin, and A Benhida, and K Peerlinck, and B Desqueper, and L Vander Elst, and R Lavend'homme, and R d'Oiron, and R Schwaab, and M Bakkus, and K Thielemans, and J G Gilles, and J Vermylen, and J M Saint-Remy
Von Willebrand factor, factor VIII and the factor VIII/von Willebrand factor complex.
October 1990, Danish medical bulletin,
Copied contents to your clipboard!